Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA) had its target price lifted by Needham & Company LLC from $10.00 to $12.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 163.16% from the stock’s previous close.

Several other analysts have also weighed in on the company. Raymond James Financial reissued a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. UBS Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Moderate Buy” and an average target price of $11.09.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $4.56 on Thursday. The firm has a fifty day moving average of $4.65 and a two-hundred day moving average of $4.53. The firm has a market cap of $1.25 billion, a P/E ratio of -13.82 and a beta of 1.02. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 26,918 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $124,091.98. Following the sale, the insider owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $109,943.89. Following the sale, the chief financial officer directly owned 1,443,786 shares in the company, valued at approximately $6,655,853.46. This trade represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 598,623 shares of company stock worth $2,822,188 in the last ninety days. 3.78% of the stock is owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TSHA. Caitong International Asset Management Co. Ltd raised its stake in Taysha Gene Therapies by 698.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock valued at $141,000 after acquiring an additional 22,373 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth $920,000. Invesco Ltd. increased its holdings in shares of Taysha Gene Therapies by 376.3% during the fourth quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock valued at $7,330,000 after purchasing an additional 1,052,987 shares during the period. Oracle Investment Management Inc. acquired a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $1,458,000. Finally, Voloridge Investment Management LLC bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at about $301,000. 77.70% of the stock is owned by institutional investors.

Key Stories Impacting Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 beats on both EPS and revenue — reported EPS of ($0.08) vs. consensus ($0.11) and revenue $5.49M vs. $1.89M consensus; management reiterated progress in the business update. Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Clinical milestone — dosing continuing in the REVEAL pivotal trial for TSHA‑102, enrollment advancing across sites and on track to complete dosing in Q2 2026; company outlined a 2026 BLA submission path, which materially de‑risks the program if timelines hold. Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Balance sheet & liquidity highlighted — management and coverage notes emphasize a strong cash position and high current/quick ratios, supporting near‑term trial execution without obvious financing pressure. Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and …
• Positive Sentiment: Analyst support — Chardan Capital reaffirmed a “buy” and set a $12 price target, signaling bullish conviction from at least one boutique healthcare analyst. Benzinga
• Neutral Sentiment: Earnings call coverage and transcripts are available for deep dives — useful for investors wanting management color on timelines, enrollment details and regulatory strategy. Taysha Gene Therapies Signals Momentum in Earnings Call
• Neutral Sentiment: Preview/coverage pieces summarize expectations and questions investors should watch on upcoming milestones (e.g., final pivotal enrollments, data timelines). Taysha (TSHA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; biotech risk remains high if clinical or regulatory timelines slip — these fundamentals temper valuation despite the recent positive headlines. Taysha Gene Therapies Stock Earnings Details

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.